High treatment failure and default rates for patients with multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa, 2000-2003

International Journal of Tuberculosis and Lung Disease

Volumn 14, Issue 4, 2010, Pages 413-419

  Brust, James C M ^a   Gandhi, N R ^a   Carrara, H ^b   Osburn, G ^c   Padayatchi, N ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

^c King George V Hospital Durban   (South Africa)

Author keywords

Drug resistance; Mycobacterium tuberculosis; South Africa; Treatment outcomes

Indexed keywords

ANTIRETROVIRUS AGENT; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; KANAMYCIN; OFLOXACIN; PYRAZINAMIDE;

ADULT; ARTICLE; DEATH; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; FEMALE; GENDER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MULTIDRUG RESISTANCE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SOUTH AFRICA; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; ANTITUBERCULAR AGENTS; CHI-SQUARE DISTRIBUTION; DEVELOPING COUNTRIES; FEMALE; HIV INFECTIONS; HUMANS; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; ODDS RATIO; PREVALENCE; PROGRAM EVALUATION; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; SOUTH AFRICA; TIME FACTORS; TREATMENT FAILURE; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 77950312476     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. World Health Organization. Anti-tuberculosis drug resistance in the world. Report no. 4. The WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance. WHO/HTM/ TB/2008.394. Geneva, Switzerland: WHO, 2008.
2. World Health Organization. Global tuberculosis control 2008: surveillance, planning, financing. WHO/HTM/TB/2008.393. Geneva, Switzerland: WHO, 2008.
3. Buthelezi S S S. Situational analysis of TB drug resistance in KwaZulu-Natal Province: Republic of South Africa. Second meeting of the WHO Task Force on XDR-TB, April 9-10, 2008. Geneva, Switzerland: WHO, 2009.
4. Weyer K, Lancaster J, Brand J, Van der Walt M J L, Medical Research Council of South Africa. Survey of tuberculous drug resistance in South Africa, 2001-2002. Pretoria, South Africa: Department of Health, 2003.
5. Gandhi N R, Moll A, Sturm A W, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368: 1575-1580.
6. Andrews J R, Gandhi N R, Moodley P, et al. Exogenous re-infection as a cause of multidrug-resistant and extensively drug-resistant tuberculosis in rural South Africa. J Infect Dis 2008; 198: 1582-1589.
7. Selwyn P A, Hartel D, Lewis V A, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320: 545-550.
8. Kleeberg H H, Koornhof H J, Palmhert H. Susceptibility testing. In: Nel E E, Kleeberg H H, Gatner E M S, eds. Laboratory manual of tuberculosis methods. 2nd ed. Pretoria, South Africa: South African Medical Research Council, 1980.
9. Laserson K F, Thorpe L E, Leimane V, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005; 9: 640-645.
10. Tahaoglu K, Torun T, Sevim T, et al. The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med 2001; 345: 170-174.
11. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003; 348: 119-128.
12. Keshavjee S, Gelmanova I Y, Farmer P E, et al. Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retro-spective cohort study. Lancet 2008; 372: 1403-1409.
13. Cox H S, Kalon S, Allamuratova S, et al. Multidrug-resistant tuberculosis treatment outcomes in Karakalpakstan, Uzbekistan: treatment complexity and XDR-TB among treatment failures. PLoS One 2007; 2: e1126.
14. Eker B, Ortmann J, Migliori G B, et al. Multidrug- and extensively drug-resistant tuberculosis, Germany. Emerg Infect Dis 2008; 14: 1700-1706.
15. Nathanson E, Lambregts-van Weezenbeek C, Rich M L, et al. Multidrug-resistant tuberculosis management in resource-limited settings. Emerg Infect Dis 2006; 12: 1389-1397.
16. Kim H R, Hwang S S, Kim H J, et al. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis 2007; 45: 1290-1295.
17. Zager E M, McNerney R. Multidrug-resistant tuberculosis. BMC Infect Dis 2008; 8: 10.
18. Orenstein E W, Basu S, Shah N S, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 153-161.
19. Banerjee R, Allen J, Westenhouse J, et al. Extensively drug-resistant tuberculosis in California, 1993-2006. Clin Infect Dis 2008; 47: 450-457.
20. Small P M, Shafer R W, Hopewell P C, et al. Exogenous re-infection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med 1993; 328: 1137-1144.
21. Salomon N, Perlman D C, Friedmann P, Buchstein S, Kreiswirth B N, Mildvan D. Predictors and outcome of multidrug-resistant tuberculosis. Clin Infect Dis 1995; 21: 1245-1252.
22. Park M M, Davis A L, Schluger N W, Cohen H, Rom W N. Outcome of MDR-TB patients, 1983-1993. Prolonged survival with appropriate therapy. Am J Respir Crit Care Med 1996; 153: 317-324.
23. Frieden T R, Sherman L F, Maw K L, et al. A multi-institutional outbreak of highly drug-resistant tuberculosis: epidemiology and clinical outcomes. JAMA 1996; 276: 1229-1235.
24. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/ 2008.402. Geneva, Switzerland: WHO, 2008.
25. O'Donnell M R, Padayatchi N, Master I, Osburn G, Horsburgh C R. Improved early results for patients with extensively drug-resistant tuberculosis and HIV in South Africa. Int J Tuberc Lung Dis 2009; 13: 855-861.
26. Holtz T H, Lancaster J, Laserson K F, Wells C D, Thorpe L, Weyer K. Risk factors associated with default from multidrugresistant tuberculosis treatment, South Africa, 1999-2001. Int J Tuberc Lung Dis 2006; 10: 649-655.
27. Geng E H, Emenyonu N, Bwana M B, Glidden D V, Martin J N. Sampling-based approach to determining outcomes of patients lost to follow-up in antiretroviral therapy scale-up programs in Africa. JAMA 2008; 300: 506-507.
28. Padayatchi N, Friedland G. Decentralised management of drug-resistant tuberculosis (MDR- and XDR-TB) in South Africa: an alternative model of care. Int J Tuberc Lung Dis 2008; 12: 978-980.
29. Scano F, Vitoria M, Burman W, Harries A D, Gilks CF, Havlir D. Management of HIV-infected patients with MDR- and XDRTB in resource-limited settings. Int J Tuberc Lung Dis 2008; 12: 1370-1375.
30. Kim H J, Kang C H, Kim Y T, et al. Prognostic factors for surgical resection in patients with multidrug-resistant tuberculosis. Eur Respir J 2006; 28: 576-580.
31. Pomerantz B J, Cleveland J C Jr, Olson H K, Pomerantz M. Pulmonary resection for multi-drug resistant tuberculosis. J Thorac Cardiovasc Surg 2001; 121: 448-453.